• Blood transfusion is an integral part of the supportive care of patients with sickle cell
diseases. The hazards of red blood cell alloimmunization and delayed hemolytic transfusion
reactions (DHTRs) complicate the treatment of patients with sickle cell diseases, particularly
since such reactions may be misinterpreted as a pain crisis, and, as a result, specific
transfusion serologic studies may not be performed. The frequency of alloimmunization in
this population has been the subject of several reports; however, the frequency of DHTRs is …